$159 Million is the total value of Avidity Partners Management LP's 33 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BAX | New | BAXTER INTL INC | $13,797,000 | – | 165,000 | +100.0% | 8.69% | – |
| HCA | New | HCA HEALTHCARE INC | $9,268,000 | – | 62,700 | +100.0% | 5.84% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $8,758,000 | – | 40,000 | +100.0% | 5.52% | – |
| ABBV | New | ABBVIE INC | $8,323,000 | – | 94,000 | +100.0% | 5.24% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $8,247,000 | – | 64,000 | +100.0% | 5.20% | – |
| ZBH | New | ZIMMER BIOMET HLDGS INC | $8,158,000 | – | 54,500 | +100.0% | 5.14% | – |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $7,776,000 | – | 130,400 | +100.0% | 4.90% | – |
| EW | New | EDWARDS LIFESCIENCES CORP | $6,299,000 | – | 27,000 | +100.0% | 3.97% | – |
| CI | New | CIGNA CORP NEW | $6,135,000 | – | 30,000 | +100.0% | 3.87% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $5,857,000 | – | 42,100 | +100.0% | 3.69% | – |
| AXNX | New | AXONICS MODULATION TECH INC | $5,764,000 | – | 208,000 | +100.0% | 3.63% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB LTD | $5,430,000 | – | 150,000 | +100.0% | 3.42% | – |
| NXTC | New | NEXTCURE INC | $5,239,000 | – | 93,000 | +100.0% | 3.30% | – |
| CTLT | New | CATALENT INC | $5,180,000 | – | 92,000 | +100.0% | 3.26% | – |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $4,700,000 | – | 232,000 | +100.0% | 2.96% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $4,462,000 | – | 780,000 | +100.0% | 2.81% | – |
| ABEO | New | ABEONA THERAPEUTICS INC | $4,333,000 | – | 1,325,000 | +100.0% | 2.73% | – |
| DXCM | New | DEXCOM INC | $4,156,000 | – | 19,000 | +100.0% | 2.62% | – |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $3,946,000 | – | 200,000 | +100.0% | 2.49% | – |
| QURE | New | UNIQURE NV | $3,941,000 | – | 55,000 | +100.0% | 2.48% | – |
| CHRS | New | COHERUS BIOSCIENCES INC | $3,862,000 | – | 214,500 | +100.0% | 2.43% | – |
| KDMN | New | KADMON HLDGS INC | $3,760,000 | – | 830,000 | +100.0% | 2.37% | – |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $3,704,000 | – | 180,000 | +100.0% | 2.33% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $3,547,000 | – | 33,000 | +100.0% | 2.24% | – |
| IMMU | New | IMMUNOMEDICS INC | $2,962,000 | – | 140,000 | +100.0% | 1.87% | – |
| EXAS | New | EXACT SCIENCES CORP | $2,867,000 | – | 31,000 | +100.0% | 1.81% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $2,587,000 | – | 210,000 | +100.0% | 1.63% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $2,310,000 | – | 54,000 | +100.0% | 1.46% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $1,367,000 | – | 15,000 | +100.0% | 0.86% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $683,000 | – | 30,000 | +100.0% | 0.43% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $473,000 | – | 1,400,000 | +100.0% | 0.30% | – |
| ARAV | New | ARAVIVE INC | $410,000 | – | 30,000 | +100.0% | 0.26% | – |
| RLMD | New | RELMADA THERAPEUTICS INC | $390,000 | – | 10,000 | +100.0% | 0.25% | – |
| New | -- | $0 | – | 0 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.